Silexion Stock Just Split 1-for-10. The Real Test Starts Now
Silexion Therapeutics Corp shares slipped 14 cents to $4.85 in midday Nasdaq trading on Wednesday, leaving the cancer-drug developer lower even as biotech exchange-traded funds gained. The stock had traded between $4.69 and $5.04 on volume of about 78,000 shares. The move matters because Silexion is only days into trading on a split-adjusted basis after a 1-for-10 reverse share split, a step that combines shares to lift the quoted price without changing an investor’s proportional ownership. The company said the action was aimed at helping it maintain compliance with Nasdaq requirements and support development of SIL204, its lead pancreatic-cancer candidate.